ACRV
Acrivon Therapeutics, Inc. Common Stock
NASDAQ: ACRV · HEALTHCARE · BIOTECHNOLOGY
$1.81
-4.74% today
Updated 2026-04-29
Market cap
$70.13M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.02
Dividend yield
—
52W range
$1 – $4
Volume
0.9M
Acrivon Therapeutics, Inc. Common Stock (ACRV) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — |
| Cost of revenue | $13000.00 | $832000.00 | $1.09M | $536000.00 | $1.01M | $1.36M |
| Gross profit | $-13000.00 | $-832000.00 | $-1.09M | $-536000.00 | $-1.01M | $-1.36M |
| Gross margin | — | — | — | — | — | — |
| R&D | $1.87M | $13.72M | $23.95M | $45.49M | $63.99M | $59.99M |
| SG&A | $1.30M | $2.47M | $8.71M | $21.08M | $25.21M | $24.12M |
| Operating income | $-3.17M | $-16.18M | $-32.66M | $-67.24M | $-89.20M | $-84.11M |
| Operating margin | — | — | — | — | — | — |
| EBITDA | $-5.29M | $-16.15M | $-32.29M | $-59.85M | $-79.55M | $-82.76M |
| EBITDA margin | — | — | — | — | — | — |
| EBIT | $-5.31M | $-16.18M | $-32.66M | $-60.39M | $-80.56M | $-84.11M |
| Interest expense | — | $59000.00 | $1.49M | — | — | — |
| Income tax | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-5.31M | $-16.24M | $-29.68M | $-60.39M | $-80.56M | $-77.91M |
| Net income growth (YoY) | — | -206.1% | -82.7% | -103.5% | -33.4% | +3.3% |
| Profit margin | — | — | — | — | — | — |